3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Prostatic Neoplasms
9
Erectile Dysfunction
9
Sexuality
2
Sexual Dysfunction, Physiological
2
Rectal Neoplasms
2
Neoplasms
2
Fatigue
2
Brain Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vascular Malformations
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Solid Tumor
1
Sarcoma
1
Radiation Injuries
1
Pre-Eclampsia
1
Postoperative Complications
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Neurologic Manifestations
1
Mental Fatigue
1
Lymphoma, Follicular
1
Lymphatic Abnormalities
1
Lymphangioma
1
Infertility
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Erectile Dysfunction Following Radical Prostatectomy
1
Cholangiocarcinoma
1
Interventions
Gemcitabine
112
Cisplatin
76
Oxaliplatin
44
pembrolizumab
34
Fluorouracil
32
Capecitabine
30
durvalumab
27
Leucovorin
26
lenvatinib
23
Magnetic Resonance Spectroscopy
15
Irinotecan
14
Nivolumab
12
Biopsy
12
Albumin-Bound Paclitaxel
12
tislelizumab
11
Specimen Handling
11
Radiofrequency Ablation
11
Drug Therapy
11
pemigatinib
10
apatinib
10
Taxes
10
Floxuridine
10
130-nm albumin-bound paclitaxel
10
Radiotherapy
9
Bevacizumab
9
Platinum
8
Folfox protocol
8
Carboplatin
8
1,2-diaminocyclohexaneplatinum II citrate
8
tremelimumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cholangiocarcinoma
×
Sildenafil Citrate
×
Clear all
NCT02106871
2017-10-27
PCC
The University of Texas Medical Branch, Galveston
Phase 1
Withdrawn